Therefore, research is ongoing to identify new targets to develop safer and more effective anti-obesity and anti-NASH drugs by improving energy metabolism, insulin sensitivity and inflammation [53,54,55,56,72,73,74,75,76,77,78,79]. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.